Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 1/2007

01-01-2007 | Case Report

Systemic lupus erythematosus complicated by dilated cardiomyopathy and severe heart failure

Authors: Celalettin Usalan, Hakan Buyukhatipoglu, Ozlem Tiryaki

Published in: Clinical Rheumatology | Issue 1/2007

Login to get access

Abstract

Systemic lupus erythematosus (SLE) is the prototype autoimmune disorder, one that is known for its many, diverse modes of presentation. In this paper, we present a further unusual presentation of SLE, that of acute onset, severe heart failure secondary to dilated cardiomyopathy. Only a few similar cases have been reported in the literature.
Literature
1.
Kasper EK, Agema WRP, Hutchins GM, Deckers JW, Hare JM, Baughman KL (1994) The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 23:586–590PubMedCrossRef
2.
Bender JR (1991) Idiopathic dilated cardiomyopathy: an immunologic, genetic, or infectious disease, or all of the above? Circulation 83:704–710PubMed
3.
The American Rheumatism Association (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271CrossRef
4.
Mandell BF (1987) Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 17(2):126–141CrossRefPubMed
5.
Badui E, Garcia-Rubi D, Robles E, Jimenez J, Juan L, Deleze M, Diaz A, Mintz G (1985) Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology 36(7):431–441PubMed
6.
Murai K, Oku H, Takeuchi K, Kanayama Y, Inoue T, Takeda T (1987) Alterations in myocardial systolic and diastolic function in patients with active systemic lupus erythematosus. Am Heart J 113:966–971CrossRefPubMed
7.
Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Sufredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO, Alling D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS (1989) A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321:1061–1068PubMedCrossRef
8.
Sandrasegaran K, Clarke CW, Nagendran V (1992) Sub-clinical systemic lupus erythematosus presenting with acute myocarditis. Postgrad Med J 68(800):475–478PubMedCrossRef
9.
Frustaci A, Gentiloni N, Caldarulo M (1996) Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus. Chest 109(1):282–284PubMed
Metadata
Title
Systemic lupus erythematosus complicated by dilated cardiomyopathy and severe heart failure
Authors
Celalettin Usalan
Hakan Buyukhatipoglu
Ozlem Tiryaki
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0123-z

Other articles of this Issue 1/2007

Clinical Rheumatology 1/2007 Go to the issue

Erratum

Spontaneous pneumomediastinum and dermatomyositis may be a not so rare association: report of a case and review of the literature

Brief Report

Low-dose methotrexate-induced pancytopenia

Letter to the Editor

Standardization is essential for a more rigorous comparison of rates: comment on the reply by Gilgil, Kacar, and Tuncer

Case Report

Retroperitoneal fibrosis and c-ANCA positivity

Brief Report

High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin’s lymphoma

Original Article

Immunoglobulin E: a new diagnostic clue for Behçet’s disease?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits